Becker's Healthcare January 17, 2024
The FDA on Jan. 16 approved Casgevy to be used as a treatment for beta-thalassemia. The move comes just over a month after the nation’s first medicine based on CRISPR gene-editing technology was approved to treat patients with sickle cell disease.
Casgevy was approved to treat patients 12 and older with beta-thalassemia, an inherited blood disorder that affects the ability to produce hemoglobin. Patients with the condition often require frequent blood transfusions.
“Today’s approval is an important step in the advancement of an additional treatment option for individuals with beta-thalassemia, a debilitating disease that places individuals at risk of many serious health problems,” Nicole Verdun, MD, director of...
Today's Sponsors
Today's Sponsor